The Medical Letter on Drugs and Therapeutics
Ruxolitinib (Jakafi) for Myelofibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ruxolitinib (Jakafi – Incyte), a janus-associated kinase (JAK) inhibitor, for treatment of myelofibrosis. Jakafi is the first JAK inhibitor to be approved for any indication and the only drug approved for treatment of myelofibrosis.

MYELOFIBROSIS — Myelofibrosis, a chronic myeloproliferative disorder, is characterized by progressive anemia, bone marrow fibrosis, splenomegaly and constitutional symptoms such as severe fatigue, low grade fever, pruritus, night sweats and weight loss. Current drug therapy is palliative and efficacy is variable. Allogeneic stem cell transplantation is potentially curative, but is not appropriate for many patients and is associated with significant morbidity and mortality.

MECHANISM OF ACTION — JAK1 and JAK2 mediate the signaling of cytokines that cause inflammation and growth factors that are important for ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ruxolitinib (Jakafi) for Myelofibrosis
Article code: 1387c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian